#ASH22: Co­gent touts da­ta on small sub­set of rare dis­ease pa­tients in bid to com­pete with Blue­print 

NEW OR­LEANS — Co­gent Bio­sciences de­liv­ered an ear­ly look at ef­fi­ca­cy and safe­ty on its ad­vanced sys­temic mas­to­cy­to­sis drug can­di­date, which the biotech hopes will help it eke out a space in the treat­ment land­scape, cur­rent­ly cov­ered by Blue­print Med­i­cines’ ap­proved Ay­vak­it.

In­vestors sent shares $COGT up about 8% Mon­day af­ter Co­gent said that 73% of a small set of pa­tients re­spond­ed to its drug, known as bezu­clas­tinib, in a pre­sen­ta­tion Sun­day night at the an­nu­al Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER